{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T05:02:50Z","timestamp":1793509370789,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012286","name":"Deputy for Research and Technology, Kermanshah University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijpddr.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T11:45:46Z","timestamp":1569239146000},"page":"156-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis"],"prefix":"10.1016","volume":"11","author":[{"given":"Mahmoud Reza","family":"Jaafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Hatamipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Hoda","family":"Alavizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Taslimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram Miramin","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Khamesipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2019.09.004_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Adler-Moore","year":"2016","journal-title":"Med. Mycol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib2","first-page":"25","article-title":"Amphotericin B lipid preparations: what are the differences?","volume":"14","author":"Adler-Moore","year":"2008","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-3659(01)00549-1","article-title":"Targeting to macrophages: role of physicochemical properties of particulate carriers\u2014liposomes and microspheres\u2014on the phagocytosis by macrophages","volume":"79","author":"Ahsan","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","article-title":"Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of America (idsa) and the american society of tropical medicine and hygiene (astmh)","volume":"96","author":"Aronson","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib5","first-page":"301","article-title":"Optimizing efficacy of Amphotericin B through nanomodification","volume":"2","author":"Barratt","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.actatropica.2012.06.004","article-title":"Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB\/c mice","volume":"124","author":"Bavarsad","year":"2012","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"Ben","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4269\/ajtmh.1995.53.162","article-title":"A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment","volume":"53","author":"Ben","year":"1995","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.14-0743","article-title":"Amphotericin B formulations and other drugs for visceral leishmaniasis","volume":"92","author":"Berman","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib10","first-page":"252","article-title":"Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation","volume":"7","author":"Bhatia","year":"2004","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s12639-014-0607-3","article-title":"Treatment of visceral leishmaniasis: anomalous pricing and distribution of AmBisome and emergence of an indigenous liposomal amphotericin B, fungisome","volume":"40","author":"Bhattacharya","year":"2016","journal-title":"J. Parasit. Dis.: Off. Organ. Indian. Soc. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/exd.13098","article-title":"Topical treatment with a two-component gel releasing nitric oxide cures C57BL\/6 mice from cutaneous leishmaniasis caused by Leishmania major","volume":"25","author":"Butsch","year":"2016","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1381612023396258","article-title":"Chemotherapy of leishmaniasis","volume":"8","author":"Croft","year":"2002","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib16","first-page":"37","article-title":"Amphotericin-B loaded vesicular systems for the treatment of topical fungal infection","volume":"4","author":"Devi","year":"2011","journal-title":"Int J Rec Adv Pharm Res"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejps.2016.10.025","article-title":"Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis","volume":"96","author":"Doppalapudi","year":"2017","journal-title":"Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0738-081X(96)00058-2","article-title":"Cutaneous leishmaniasis: clinical aspect","volume":"14","author":"Dowlati","year":"1996","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1128\/AAC.26.5.745","article-title":"Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals","volume":"26","author":"El-On","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2008.05.002","article-title":"Liposomes and skin: from drug delivery to model membranes","volume":"34","author":"El Maghraby","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib21","first-page":"269","article-title":"Safety evaluation of nano-liposomal formulation of amphotericin b (sinaampholeish) in animal model as a candidate for treatment of cutaneous leishmaniasis","volume":"12","author":"Eskandari","year":"2018","journal-title":"J. Arthropod-Borne Dis."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib22","first-page":"197","article-title":"Safety evaluation of topical application of nano-liposomal form of amphotericin b (sinaampholeish) on healthy volunteers: phase i clinical trial","volume":"14","author":"Eskandari","year":"2019","journal-title":"Iran. J. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib23","article-title":"Drug resistance in eukaryotic microorganisms","volume":"1","author":"Fairlamb","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib24","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.42.12.3092","article-title":"Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B","volume":"42","author":"Frankenburg","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib25","first-page":"538","article-title":"Topical treatment for cutaneous leishmaniasis","volume":"3","author":"Garnier","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1211\/jpp.59.1.0006","article-title":"Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis","volume":"59","author":"Garnier","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib27","first-page":"75","article-title":"Liposomes from vegetable phosphatidylcholine: their production and effects on the skin","volume":"109","author":"Ghyczy","year":"1994","journal-title":"Cosmet. Toilet."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib28","doi-asserted-by":"crossref","first-page":"11584","DOI":"10.1021\/acsnano.7b06524","article-title":"Revealing dynamics of accumulation of systemically injected liposomes in the skin by intravital microscopy","volume":"11","author":"Griffin","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1039\/C5CS00674K","article-title":"New approaches from nanomedicine for treating leishmaniasis","volume":"45","author":"Guti\u00e9rrez","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030162","article-title":"Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites","volume":"3","author":"Hadighi","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib32","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1002\/ange.200900111","article-title":"Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery","volume":"121","author":"Huang","year":"2009","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02525-16","article-title":"Biodistribution and in vivo antileishmanial activity of 1, 2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine liposome-intercalated amphotericin B","volume":"61","author":"Iman","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpharm.2011.01.044","article-title":"Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a distigmasterylhemisuccinoyl-glycero-phosphocholine liposome-intercalated amphotericin B","volume":"408","author":"Iman","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib35","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01319-08","article-title":"Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB\/c mice","volume":"53","author":"Jaafari","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib36","series-title":"Topical Liposomal Compositions for Delivering Hydrophobic Drugs and Methods Preparing Same","author":"Jaafari","year":"2015"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.exppara.2014.04.013","article-title":"Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB\/c mice","volume":"143","author":"Kalat","year":"2014","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.actatropica.2019.05.018","article-title":"Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB\/c mice","volume":"196","author":"Kavian","year":"2019","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib39","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/jdv.14434","article-title":"Cutaneous Leishmania tropica in children: report of three imported cases successfully treated with liposomal amphotericin B","volume":"32","author":"Kn\u00f6pfel","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000034","article-title":"Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL\/6 Model","volume":"1","author":"Lecoeur","year":"2007","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib41","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.bbamem.2013.05.010","article-title":"Molecular dynamics simulations of the interactions of DMSO, mono-and polyhydroxylated cryosolvents with a hydrated phospholipid bilayer","volume":"1828","author":"Malajczuk","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijpharm.2003.10.031","article-title":"Stability and transdermal absorption of topical amphotericin B liposome formulations","volume":"270","author":"Manosroi","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jlb.47.2.187","article-title":"Macrophage\u2010parasite interactions in leishmania infections","volume":"47","author":"Mau\u00ebl","year":"1990","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib44","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1128\/AAC.02343-12","article-title":"Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly (\u03b1-Glutamic Acid) complex","volume":"57","author":"Mohamed-Ahmed","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.2042-7158.1998.tb03304.x","article-title":"Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats","volume":"50","author":"Murakami","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/dth.12377","article-title":"Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report","volume":"29","author":"Mushtaq","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib47","first-page":"15","article-title":"Anthroponotic cutaneous leishmaniasis in the city of Bam, southeast Iran","volume":"24","author":"Nadim","year":"1995","journal-title":"Iran. J. Public Health"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib48","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0365-05962011000600005","article-title":"A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis","volume":"86","author":"Neves","year":"2011","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.colsurfb.2015.12.003","article-title":"Topical amphotericin B in ultradeformable liposomes: formulation, skin penetration study, antifungal and antileishmanial activity in vitro","volume":"139","author":"Perez","year":"2016","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00403-011-1166-4","article-title":"Liposomal systems as drug delivery vehicles for dermal and transdermal applications","volume":"303","author":"Pierre","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: a 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0005-2736(84)90521-2","article-title":"The effects of charge and size on the interaction of unilamellar liposomes with macrophages","volume":"772","author":"Schwendener","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1166\/jbn.2010.1121","article-title":"Development and performance evaluation of amphotericin B transfersomes against resistant and sensitive clinical isolates of visceral leishmaniasis","volume":"6","author":"Singodia","year":"2010","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib54","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1468-3083.2010.03908.x","article-title":"Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica","volume":"25","author":"Solomon","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/clinids\/20.1.47","article-title":"Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin\/methylbenzethonium chloride and injectable meglumine antimonate","volume":"20","author":"Soto","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib56","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijpharm.2012.01.045","article-title":"Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment","volume":"427","author":"Srisuk","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib57","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/978-1-4939-3387-7_34","article-title":"DNA integration in leishmania genome: an application for vaccine development and drug screening","volume":"1403","author":"Taheri","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib58","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/jphp.12548","article-title":"Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB\/c mouse model","volume":"68","author":"Van Bocxlaer","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.actatropica.2017.06.004","article-title":"Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana","volume":"173","author":"Varikuti","year":"2017","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpddr.2018.04.001","article-title":"Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome\u00ae and AmBisome\u00ae in murine cutaneous leishmaniasis","volume":"8","author":"Wijnant","year":"2018","journal-title":"Int. J. Parasitol. Drug Resist."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib61","series-title":"Pharmaceutical Formulation Comprising Cyclosporin and Use Thereof","author":"Wohlrab J","year":"2005"},{"key":"10.1016\/j.ijpddr.2019.09.004_bib62","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2019.09.004_bib63","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/01.inf.0000069794.83612.2f","article-title":"Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B","volume":"22","author":"Zvulunov","year":"2003","journal-title":"Pediatr. Infect. Dis. J."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320719300545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320719300545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:49:37Z","timestamp":1761922177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320719300545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":63,"alternative-id":["S2211320719300545"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.09.004","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}